Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
Engage Bio is a Y Combinator company in the Winter 2022 batch. Its directory entry describes it as: Potent, durable, and redosable non-viral genetic medicines (Y Combinator directory entry, March 17, 2022).
Sell to companies like Engage Bio? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2022-03-17 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Engage Bio.
Free to see. No signup.
More on Engage Bio and the records around it.
Same batch, Healthcare first.
Get an email when Engage Bio changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Engage Bio raises, hires or launches. No email unless you switch it on.
Watch Engage Bio →Get the full cited report on Engage Bio
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Engage Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Engage Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Engage Bio covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Engage BioYou get an alert in MentionFox the next time this company shows up.
If you're behind Engage Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Engage Bio. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-engage-bio